Hilleman Partners With Bharat For Cholera Vaccine, Phase III Start Next Year
Vaccine specialist Hilleman announces partnership with another Indian firm, Bharat Biotech, to develop, manufacture and commercialize its simpler and cheaper oral cholera vaccine.
You may also be interested in...
India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.
Indian vaccine research organization Hilleman Laboratories says it is hoping to get its "new design", cheaper cholera vaccine licensed in Bangladesh this year and that the next step will be to seek to make it available to UN agencies amid remaining global inoculation need.
Hilleman Laboratories' CEO believes the Indian venture’s oral cholera vaccine could become the best in its class, telling Scrip cost-effectiveness is critical amid growing budgetary strains and outlining plans for a convenient tablet form.